Speed & Scale in the Great Disruption. As we worked with providers, innovators and experts around the world to understand the trends most likely to drive change in life science clinical and commercial engagement, twenty quickly stood out.
Read MoreIn a time of deep unrest amid significant social and health inequity, life sciences leaders are confronting calls to address systemic racism and inequities in the biopharmaceutical industry.
Read ArticleThat healthcare is somehow its own thing, separate and distinct from a customer’s bigger world and cultural context, was for a long time taken for granted. Its lab-borne products are complex, often life-saving creations. They’re the stuff of doctor’s offices and hospitals.
Read ArticleReport April 7, 2020
Life sciences companies have a variety of tools to demonstrate the value of their medicines in the real world, but any innovative agreement or study should definitively answer these five questions.
Report March 30, 2020
In this episode of our Coronavirus Special Edition Series, Syneos Health CEO Alistair Macdonald discusses the unique decisions to be made as a pharmaceutical organization practicing corporate responsibility in the name of public health.
Report March 27, 2020
Payer perspectives on reimbursement hurdles can help DTx companies map the journey to real-world utilization and market success.
Report March 25, 2020
Often life sciences marketers must work with less than perfect insights when devising their channel strategies. Want to learn how to improve success rate by applying “Design Thinking” in multichannel marketing?
Report March 19, 2020
Virtual delivery requires you to rethink your content and approaches. Through the many successful online meetings we’ve run, we’ve learned how to help make your virtual meeting a success.
Report March 18, 2020
Communities across the world are facing unprecedented times with a global pandemic affecting over 100+ countries. COVID-19 has created uncertainty, unparalleled business disruptions and shaken up the global workforce.
Report March 17, 2020
The COVID-19 (coronavirus) outbreak continues to grow worldwide – recently declared by the World Health Organization as a global pandemic – with widespread personal, medical, and business implications.
Report March 16, 2020
Syneos Health Value & Access surveyed pharmacy and medical directors responsible for more than 100 million lives. We talked to national and regional payers, insurers, IDNs and hospitals to get a complete picture of key challenges, unmet needs and information sources.
Report February 7, 2020
Vanela Bushi (Director, Portfolio & Transaction Strategy) discusses one of the Trends 2020 - blockchain as a source of trust. Available in the latest edition of PharmaTimes magazine.
Report February 5, 2020
The point of care has been steadily shifting away from where the clinic exists to wherever the patient goes. Listen to this Syneos Health podcast for the factors impacting this shift, and what it all means for developers, healthcare providers, and patients.
Report December 12, 2019
Listen to our podcast with Jessica Shull, European Lead for the Digital Therapeutics Alliance, an international non-profit trade association of industry leaders and stakeholders engaged in the evidence-driven advancement of digital therapeutics.
Report December 11, 2019
Digital therapeutics have been hailed as a game-changer for pharma and patients, but are they keeping up with the hype? Pharmaphorum caught up with the Syneos Health team, including Skye Hodson, Alex Brock and Duncan Arbour, to discuss their experience.
Report December 11, 2019
Improving clinical trial recruitment has long been a priority for pharma, but despite having a plethora of new innovations at their disposal, along with a sincere commitment to patient centricity, the industry still struggles to get patients engaged with trials.
Report December 9, 2019
The Biggest Shifts Changing Lives and Life Sciences
Report December 4, 2019
Catch Meg Alexander, Head, Reputation & Risk Management Practice at Syneos Health, on RARECast - a podcast focused on the intersection of rare disease with business, science, and policy.
Report November 22, 2019
Translating caregiver insights into marketing action. Part of our Caregiver Insights Series.
Report November 21, 2019
Drug developers and regulators are expanding the use of real world evidence to design, test and review rare disease treatments. But market access challenges persist as payers in the U.S. and Europe continue to express doubts. Our new survey sheds light on the perception gap.
Report November 5, 2019
Is Europe catching up (or pioneering the way) in digital therapeutics?
Report November 1, 2019
In just the past five years, significant changes have occurred in how new drugs come to market. Demands for real world evidence and patient-reported outcomes are changing how and when new drugs file for approval.
Report October 31, 2019
Patient advocacy has evolved over time, and with it, patient advocate archetypes have emerged. Listen and learn about the five types of advocates (the Caregiver, the Creator, the Citizen, the Magician, and the Rebel).
Report October 15, 2019
In this PharmaTimes article, Duncan Arbour, SVP Innovation at Syneos Health Communications Europe, talks about the need for being faster to what really matters and finding the right protocols for patients.
Report September 30, 2019
In this book, we teamed up a behavioral scientist and a healthcare communicator to work together to create one clear picture of what we know and how we can apply it in the everyday work of helping more people live healthier lives.
Report September 25, 2019
Why do people make good (and bad) decisions about their health? How can we help motivate them to change and give them the resilience to try and try again? Our industry and our world are obsessed with those questions right now.
Report September 25, 2019
To help our pharma clients elevate customer relationships, we created a dedicated assessment methodology to define a multi-dimensional measure of trust. Learn how it can be used to establish more effective customer communication in this PMLiVE article.
Report September 17, 2019
In this guest blog, Keri Mcdonough, Lead, Advocacy and Patient Relations at Syneos Health Communications shares her insight on how to assemble a patient advisory board that accurately and effectively represents the patient voice.
Report September 13, 2019
Despite parallel efforts by biopharmaceutical innovators, the demographics of clinical trials today still do not reflect the racial, ethnic or gender diversity of target patient populations around the world.
Report August 16, 2019
PIE – or Preapproval Information Exchange – refers to the communication of clinical and health care economic information on therapies in development between U.S. population health decision makers and drug manufacturers prior to regulatory approval.
Report July 31, 2019
Our team discusses the digital therapeutics landscape, the opportunities for both biopharma and tech companies, regulatory and payer hurdles, and more.
Report July 9, 2019
Coverage can be the entry or roadblock to getting your product into the patient’s hands. The trend toward consolidation means there are fewer opportunities for pharma brands to tell their story and demonstrate their product’s value.
Report June 10, 2019
The biopharmaceutical market has evolved quite a bit over the last five to 10 years. As more emerging companies are opting to commercialize on their own, they can no longer look to the “tried and true,” traditional strategies for bringing a therapy to market.
Already have a RSS feed reader?
